{"id":1305,"date":"2004-01-01T12:00:00","date_gmt":"2004-01-01T11:00:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2004\/neue-arzneimittel-2"},"modified":"2022-03-17T14:10:32","modified_gmt":"2022-03-17T13:10:32","slug":"neue-arzneimittel-2","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2004\/neue-arzneimittel-2","title":{"rendered":"Neue Arzneimittel"},"content":{"rendered":"<p>Der Arzneiverordnungs-Report 2003 beleuchtet kritisch das Verordnungsverhalten, wie hier an einigen Beispielen dargestellt. Er stellt an sehr vielen Stellen \u201dEinsparpotenziale\u201d fest. Dem m\u00f6chte man zun\u00e4chst zustimmen. Das Wort suggeriert aber, da\u00df weniger Geld im Gesundheitswesen ausgegeben werden k\u00f6nnte. Dem kann man nat\u00fcrlich nicht generell zustimmen. Zu gro\u00df sind n\u00e4mlich die Defizite in fl\u00e4chendeckender Prophylaxe und [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Der Arzneiverordnungs-Report 2003 beleuchtet kritisch das Verordnungsverhalten, wie hier an einigen Beispielen dargestellt. Er stellt an sehr vielen Stellen \u201dEinsparpotenziale\u201d fest. Dem m\u00f6chte man zun\u00e4chst zustimmen. Das Wort suggeriert aber, da\u00df weniger Geld im Gesundheitswesen ausgegeben werden k\u00f6nnte. Dem kann man nat\u00fcrlich nicht generell zustimmen. Zu gro\u00df sind n\u00e4mlich die Defizite in fl\u00e4chendeckender Prophylaxe und [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[1146,255,523,524,3175,526,1901,919,1900,1231,1892,1340,1341,638,413,663,834,924,1904,257,1730,1876,157,1332,1867,939,803,802,520,521],"class_list":["post-1305","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-acarbose","tag-arzneimittel","tag-arzneimittelverordnungen","tag-arzneiverordnungen","tag-arzneiverordnungs-report-2003","tag-buchbesprechung","tag-darbepoetin-alfa","tag-desloratadin","tag-dexibuprofen","tag-galantamin","tag-gatifloxacin","tag-glatirameracetat","tag-glatiramerazetat","tag-glibenclamid","tag-glimepirid","tag-glyburid","tag-imatinib","tag-levocetirizin","tag-lopinavir","tag-medikamente","tag-metformin","tag-nateglinid","tag-orale-antidiabetika","tag-pioglitazon","tag-rosiglitazon","tag-telithromycin","tag-tyrosinkinase-hemmer","tag-tyrosinkinase-inhibitoren","tag-verordnungsverhalten","tag-verschreibungsverhalten"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1305","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1305"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1305\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1305"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1305"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1305"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}